Aimed Alliance Raising Issues with BSBC of Alabama’s Prior Authorization Policy for Treatment of Degenerative Eye Diseases


On July 2, 2021, Aimed Alliance sent a letter to Blue Cross Blue Shield of Alabama (BCBS AL) in response to a new prior authorization policy, effective July 1, 2021, for a medication to treat degenerative eye diseases.[1] The policy requires patients with neovascular (wet) age-related macular degeneration (Wet AMD), macular edema following retinal vein occlusion (MEfRVO), diabetic macular edema (DME), and diabetic retinopathy (DR) to try and fail on an off-label, compounded medication before accessing a medication that is FDA approved for such conditions. If a medication to treat these eye conditions is ineffective, patients can experience rapid and severe loss of central vision.[2] Therefore, Aimed Alliance recommended that BCBS AL amend its prior authorization policy to remove the step therapy requirements for patients with Wet AMD, MEfRVO, DME, and DR. Read the letter here.





Comments are closed.